Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The recently published study by Zang et al. offers valuable insight into PSMA-PET/CTbased response assessment in patients with oligometastatic prostate cancer (PCa) undergoing stereotactic ablative body radiotherapy (SABR), demonstrating an impressive 5-year local control rate of 86 % and progressive reduction in SUVmax values across follow-up intervals [1]. While the findings reinforce the utility of PSMAPET/CT as a potential biomarker for local tumor control, certain methodological and interpretive issues merit deeper consideration.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12361593 | PMC |
| http://dx.doi.org/10.1016/j.ctro.2025.101031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives.
Clin Transl Oncol
September 2025
Department of Radiation Oncology, Vithas La Milagrosa University Hospital, Madrid, 28010, Spain.
This narrative review analyzes current evidence comparing single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy for localized prostate cancer. These ultra-hypofractionated strategies deliver high-precision ablative doses while minimizing exposure to normal tissues. SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience.
View Article and Find Full Text PDFImproved local control using higher dose SBRT in metastatic sarcoma patients.
Radiat Oncol
September 2025
Department of Breast Sarcoma and Endocrine Tumors, Karolinska University Hospital, Stockholm, Sweden.
Background: Stereotactic Body Radiotherapy (SBRT) has been proven to be a safe and effective alternative to surgery in patients with metastatic primary sarcoma. However, data describing tumor response in relation to the given radiotherapy dose is lacking. Therefore, this study aims at analyzing efficacy and dose-response relationship in a retrospective cohort.
View Article and Find Full Text PDFPatterns of immunity changes predict response to stereotactic ablative radiotherapy in early non-small-cell lung cancer.
Int J Radiat Oncol Biol Phys
September 2025
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Smoluchowskiego 17 str., 80-215, Gdańsk, Poland.
Background: Stereotactic Ablative Radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC) can stimulate an immune response against cancer. We evaluated changes in peripheral lymphocyte subpopulations and cytokines levels after SABR in patients with early-stage NSCLC. We examined how these changes relate to overall survival (OS) and disease-free survival (DFS).
View Article and Find Full Text PDFEfficacy of Stereotactic Ablative Body Radiotherapy (SABR) in uncommon subtypes of primary kidney cancer: An analysis from the International Radiosurgery Oncology Consortium of the Kidney.
Int J Radiat Oncol Biol Phys
September 2025
Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Background: While stereotactic ablative body radiotherapy (SABR) is associated with excellent local control for primary renal cell carcinoma (RCC), outcomes based on clear-cell (ccRCC) and non-clear cell (nccRCC) histologies are not well defined.
Methods And Materials: Individual data of adult patient with biopsy confirmed primary RCC receiving SABR between 2007 and 2021 from 16 institutions in Australia, Canda, Germany, Japan and USA pooled. Patients with metastatic disease or upper tract urothelial carcinoma were excluded.
A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC).
BMC Cancer
September 2025
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Background: Anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) immunotherapy promotes systemic anti-tumor immunity through expanding neoantigen-specific CD8 + T cells, but it is less effective in patients with liver metastases. Nearly 20% of non-small cell lung cancer (NSCLC) patients develop liver metastases, and these patients are characterized by fewer and less active effector T cells. Preclinical work has shown that liver metastases cause systemic immunosuppression through siphoning neoantigen-specific CD8 + T cells from systemic circulation with subsequent macrophage-mediated intrahepatic death.
View Article and Find Full Text PDF